Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.

Elena Cortés-VicenteRodrigo Álvarez-VelascoFrancesc Pla-JuncaRicard Rojas-GarciaCarmen ParadasTeresa SevillaCarlos CasasnovasMaría Teresa Gómez-CaravacaJulio PardoAlba Ramos-FransiAna Lara Pelayo-NegroGerardo Gutiérrez-GutiérrezJanina Turon-SansAdolfo López de MunainAntonio Guerrero-SolaIvonne JericóMaría Asunción MartínMaría Dolores MendozaGermán MorísBeatriz Vélez-GómezTania Garcia-SobrinoElba Pascual-GoñiDavid Reyes-LeivaIsabel IllaEduard Gallardo

Published in: Annals of clinical and translational neurology (2022)

In this study, 8.5% of MG patients were drug-refractory. New more specific drugs are needed to treat drug-refractory MG patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
emergency department